The antiserum was produced against synthesized peptide derived from human PLCB3 around the phosphorylation site of Ser1105. AA range:1071-1120

Phospho-PLC β3 (S1105) Polyclonal Antibody detects endogenous levels of PLC β3 protein only when phosphorylated at S1105.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):NNsIS

PLCB3

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3

PLCB3 ;
1-phosphatidylinositol 4 ;
5-bisphosphate phosphodiesterase beta-3 ;
Phosphoinositide phospholipase C-beta-3 ;
Phospholipase C-beta-3 ;
PLC-beta-3

This gene encodes a member of the phosphoinositide phospholipase C beta enzyme family that catalyze the production of the secondary messengers diacylglycerol and inositol 1,4,5-triphosphate from phosphatidylinositol in G-protein-linked receptor-mediated signal transduction. Alternative splicing results in multiple transcript variants.[provided by RefSeq, May 2010],

Catalytic activity:1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate + H(2)O = 1D-myo-inositol 1,4,5-trisphosphate + diacylglycerol.,cofactor:Calcium.,Function:The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes.,similarity:Contains 1 C2 domain.,similarity:Contains 1 PI-PLC X-box domain.,similarity:Contains 1 PI-PLC Y-box domain.,subunit:Interacts with SHANK2 (By similarity). Interacts with LPAR2.,

Cytoplasm . Membrane . Nucleus . And particulate fractions. .

Epithelium,Uterus,

>>Inositol phosphate metabolism ;
>>Metabolic pathways ;
>>Rap1 signaling pathway ;
>>Calcium signaling pathway ;
>>cGMP-PKG signaling pathway ;
>>Chemokine signaling pathway ;
>>Phosphatidylinositol signaling system ;
>>Sphingolipid signaling pathway ;
>>Phospholipase D signaling pathway ;
>>Adrenergic signaling in cardiomyocytes ;
>>Vascular smooth muscle contraction ;
>>Wnt signaling pathway ;
>>Apelin signaling pathway ;
>>Gap junction ;
>>Platelet activation ;
>>Neutrophil extracellular trap formation ;
>>NOD-like receptor signaling pathway ;
>>Circadian entrainment ;
>>Long-term potentiation ;
>>Retrograde endocannabinoid signaling ;
>>Glutamatergic synapse ;
>>Cholinergic synapse ;
>>Serotonergic synapse ;
>>Dopaminergic synapse ;
>>Long-term depression ;
>>Taste transduction ;
>>Inflammatory mediator regulation of TRP channels ;
>>Insulin secretion ;
>>GnRH signaling pathway ;
>>Estrogen signaling pathway ;
>>Melanogenesis ;
>>Thyroid hormone synthesis ;
>>Thyroid hormone signaling pathway ;
>>Oxytocin signaling pathway ;
>>Glucagon signaling pathway ;
>>Renin secretion ;
>>Aldosterone synthesis and secretion ;
>>Relaxin signaling pathway ;
>>Cortisol synthesis and secretion ;
>>Parathyroid hormone synthesis, secretion and action ;
>>GnRH secretion ;
>>AGE-RAGE signaling pathway in diabetic complications ;
>>Cushing syndrome ;
>>Growth hormone synthesis, secretion and action ;
>>Endocrine and other factor-regulated calcium reabsorption ;
>>Salivary secretion ;
>>Gastric acid secretion ;
>>Pancreatic secretion ;
>>Carbohydrate digestion and absorption ;
>>Alzheimer disease ;
>>Huntington disease ;
>>Spinocerebellar ataxia ;
>>Pathways of neurodegeneration - multiple diseases ;
>>Shigellosis ;
>>Chagas disease ;
>>African trypanosomiasis ;
>>Amoebiasis ;
>>Human cytomegalovirus infection ;
>>Pathways in cancer ;
>>Diabetic cardiomyopathy ;
>>Lipid and atherosclerosis